An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Viridian Therapeutics Sees Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease On May 5, Viridian Therapeutics, Inc., announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 Trial On April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Foundayo™ Weight Loss GLP-1 Pill On April 1, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Novo Nordisk’s Awiqli® On March 26, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism On January 7, Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by all forms...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience On December 4, Insulet Corporation, announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery...
